Research institution
Institut du Cancer de Montpellier - Val d'Aurelle Clinical Trials
Studies where Institut du Cancer de Montpellier - Val d'Aurelle is the lead sponsor: what is enrolling now, by phase, condition and country.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 50Thyroid Cancer, Prostate Cancer
Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department
Development of a clinico-biological database allowing the provision of clinical data and corresponding biological materials to the medical and scientific community.
- Conditions
- Thyroid Cancer, Prostate Cancer, Neuroendocrine Tumors, SSTR Positive Tumors
- Trial name
- BCB RIV (NCT04104529)
- Testing
- Biological collection, tumor collection
- Where
- 4 sites in France
- Volunteers
- 350 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Breast Cancer, Physiotherapy
Evaluation of the Impact of Pre-habilitation Using Physiotherapy and Mechanical Stimulation on Shoulder Pain and Mobility in Patients Undergoing Breast Reconstruction Using a Latissimus Dorsi Flap
Each year in France, nearly 59,000 new cases of breast cancer are diagnosed, and approximately 22,000 mastectomies are performed. Among these patients, 30% choose to undergo breast reconstruction.
- Conditions
- Breast Cancer, Physiotherapy, Breast Reconstruction, Latissimus Dorsi Flap
- Trial name
- PREHAB KINELGD (NCT07418060)
- Testing
- Prehabilitation with physiotherapy including mechanostimulation, No Prehabilitation with physiotherapy including mechanostimulation
- Where
- 2 sites in France
- Volunteers
- 96 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Rectal Cancer, Chemoradiotherapy
Multidimensional Study Designed to Develop a Methodological Framework Based on MRI Data to Predict Pathological Complete Response (pCR) in Patients With Locally Advanced Rectal Cancer After Neoadjuvant Treatment
Rectal cancer presents a significant global health challenge. Despite improvements in clinical outcomes, significant disparities persist across Europe.
- Conditions
- Rectal Cancer, Chemoradiotherapy, Mri
- Trial name
- RESTAGE (NCT07404228)
- Testing
- questionnaire completion
- Where
- France
- Volunteers
- 115 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Rectal Cancer, Colon Cancer
Contribution of Preserving the Superior Left Colic Artery to the Vascularization of the Descending Colon Prior to Colorectal Anastomosis During Left-Sided or Rectal Resections for Colorectal or Ovarian Cancer. (Revascularisation Colique)
Colorectal cancers and ovarian cancers are respectively the 2nd and 5th cause of cancer mortality in France. Surgical resection is a crucial step in the therapeutic management of colorectal cancers.
- Conditions
- Rectal Cancer, Colon Cancer, Ovarian Cancer
- Trial name
- NCT07098182
- Testing
- Clamping and restauration of arterial blood of the inferior mesenteric artery
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Locally Advanced Malignant Neoplasm, Rectal Carcinoma
Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma
Locally advanced rectal carcinoma raise the issue of both the oncological control, local and general, and the therapeutic morbidity.
- Trial name
- GRECCAR14 (NCT04749108)
- Testing
- Induction chemotherapy - modified FOLFIRINOX regimen, Early tumor response evaluation by MRI volumetry, Radiochemotherapy Cap 50
- Where
- 30 sites in France
- Volunteers
- 1,075 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Cancer Survivors, Peripheral Neuropathic Pain
Evaluating Laser Photobiomodulation for the Treatment of Neuropathic Pain in Chemotherapy-induced Peripheral Neuropathy in Cancer Patients
Chemotherapy-induced peripheral neuropathy (CIPN) (including taxanes, platinum, al pervenche from Madagascar alkaloids...), is a frequent secondary effect of treatments: 68% at 1-month post-chemotherapy, 60% at 3 months and 30%…
- Trial name
- NEUROdoux (NCT06834685)
- Testing
- Photobiomodulation sessions
- Where
- 2 sites in France
- Volunteers
- 70 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Pediatric Oncology, Radiotherapy
Effect of the MIROKI Companion Robot on Anxiety in Pediatric Radiotherapy
Pediatric radiotherapy is an anxiety-provoking situation that can, on one hand, impair the child's cooperation and require sedation, and on the other hand,burden the care pathway by generating significant anxiety in both the…
- Conditions
- Pediatric Oncology, Radiotherapy, Parent
- Trial name
- KOKORO01 (NCT07645950)
- Where
- France
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Glioma
Using the Epitranscriptome to Diagnose and Treat Gliomas
Diffuse gliomas are among the most common tumors of the central nervous system, with high morbidity and mortality and very limited therapeutic possibilities.
- Trial name
- EPIGLIO (NCT06575452)
- Testing
- Blood, urine and tumoral tissue samples, Tumoral tissue samples
- Where
- 2 sites in France
- Volunteers
- 228 people, healthy volunteers welcome
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Neuroendocrine Tumors, Intestinal Well Differentiated Endocrine Tumor
Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET
In France, since the reimbursement of Lutathera®, this treatment is allowed for retreatment if patients still fulfill the criteria of its indication and 4 news cycles could be proposed.
- Conditions
- Neuroendocrine Tumors, Intestinal Well Differentiated Endocrine Tumor, Progressive Disease
- Trial name
- ReLUTH (NCT04954820)
- Testing
- Lutathera
- Where
- 28 sites in France
- Volunteers
- 146 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Breast Cancer
Evaluation of the Efficacy of a Physical Therapy-yoga-patient Educational Program for Breast Cancer Patients With Pain Due to Hormonal Therapy Treatment.
As much as 50% of patients treated with hormonotherapy (HT) for breast cancer (BC) suffer from osteoarticular pain during treatment.
- Trial name
- SKYPE2 (NCT04457895)
- Testing
- educational yoga program, no intervention
- Where
- 7 sites in France
- Volunteers
- 108 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Completed, with results posted
All 3Breast Cancer, Biopsy Wound
Pain Monitoring After Breast Biopsy: Benefit of E-health
Each year, approximately 1500 breast biopsies (1000 microbiopsies and 500 macrobiopsies) are performed in the radiologic department of the Montpellier Cancer Institute (ICM).
- Trial name
- BIO-PSY (NCT04456920)
- Testing
- phone consultation, e-PRO self-completed via connected objects (tablet/phone), visit
- Where
- France
- Volunteers
- 193 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Metastatic Colorectal Cancer
Safety, Tolerability and Efficacy of Regorafenib in Combination With FOLFIRINOX in Patients With Colorectal Cancer
Safety, tolerability and efficacy of regorafenib in combination with FOLFIRINOX in patients with RAS-mutated metastatic colorectal cancer: a dose-escalation, phase I/II trial
- Trial name
- FOLFIRINOX-R (NCT03828799)
- Testing
- Folfirinox + regorafenib
- Where
- 4 sites in France
- Volunteers
- 13 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Breast Carcinoma
Intraoperative Radiotherapy After Local Recurrence in Breast Cancer
The investigators propose a prospective, multicenter, single arm Phase II design to evaluate the feasibility of repeated breast-conserving surgery combined with re- irradiation using IORT after local recurrence of breast…
- Trial name
- RE-IORT01 (NCT02386371)
- Testing
- tumorectomy, Intra Operative Radiotherapy
- Where
- 8 sites in France
- Volunteers
- 66 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle